SCHEMBL6531373

SCHEMBL6531373

O=C(NCc1ccccc1)N1CCC(Nc2ccnc3[nH]c(=O)c4ccccc4c23)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 1/20 0.49
NPSR1 Q6W5P4 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
F2 P00734 1/20 0.47
PRSS1 P07477 1/20 0.47
JUN P05412 2/20 0.47
MAPK8 P45983 2/20 0.47
MAPK9 P45984 2/20 0.47
HRH3 Q9Y5N1 1/20 0.47
MAPK10 P53779 1/20 0.47
AURKA O14965 2/20 0.47
POLB P06746 1/20 0.46
USP2 O75604 1/20 0.45
MAPT P10636 1/20 0.45
MAPK13 O15264 1/20 0.45
CHEK2 O96017 1/20 0.45
NTRK1 P04629 1/20 0.45
RET P07949 1/20 0.45
HCK P08631 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12787353 0.93 ALDH1A1 (0.50) MEN1KMT2AAURKAAURKB
SCHEMBL6524188 0.90 AURKA (0.48) MEN1KMT2AJUNMAPK8MAPK9
SCHEMBL6526955 0.87 AURKA (0.47) AURKAMAPK13CHEK2NTRK1RET
SCHEMBL6522039 0.86 AURKA (0.50) JUNMAPK8MAPK9MAPK10AURKA
SCHEMBL6517847 0.86 UTS2R (0.49) GRIN2BNPSR1JUNMAPK8MAPK9
SCHEMBL6521481 0.84 AURKA (0.46) AURKAPOLBMAPK13CHEK2NTRK1
SCHEMBL6532632 0.83 ROCK2 (0.53) NPSR1MEN1KMT2AHRH3AURKA
SCHEMBL6520619 0.79 AURKA (0.49) AURKAMAPK13CHEK2NTRK1RET
SCHEMBL6521959 0.78 AURKA (0.51) AURKAMAPK13CHEK2NTRK1RET
SCHEMBL6530953 0.78 AURKA (0.45) AURKAMAPK13CHEK2NTRK1RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 GRIN2B 3429/4885NPSR1 3688/4885MEN1 3455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.